196 related articles for article (PubMed ID: 34958922)
41. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
42. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
43. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
[TBL] [Abstract][Full Text] [Related]
45. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
Lai J; Wang HL; Zhang X; Wang H; Liu X
Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
[TBL] [Abstract][Full Text] [Related]
47. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.
Calleja JL; Rivera-Esteban J; Aller R; Hernández-Conde M; Abad J; Pericàs JM; Benito HG; Serra MA; Escudero A; Ampuero J; Lucena A; Sánchez Y; Arias-Loste MT; Iruzubieta P; Romero-Gómez M; Augustin S; Crespo J
Liver Int; 2022 Aug; 42(8):1783-1792. PubMed ID: 35643936
[TBL] [Abstract][Full Text] [Related]
48. Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016.
Ciardullo S; Perseghin G
Liver Int; 2023 Feb; 43(2):340-344. PubMed ID: 36565051
[TBL] [Abstract][Full Text] [Related]
49. Nonalcoholic fatty liver disease in lean individuals in the United States.
Younossi ZM; Stepanova M; Negro F; Hallaji S; Younossi Y; Lam B; Srishord M
Medicine (Baltimore); 2012 Nov; 91(6):319-327. PubMed ID: 23117851
[TBL] [Abstract][Full Text] [Related]
50. A population-based study on the prevalence of NASH using scores validated against liver histology.
Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
[TBL] [Abstract][Full Text] [Related]
51. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
52. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
53. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome.
Kositamongkol C; Charernboon T; Chaisathaphol T; Washirasaksiri C; Auesomwang C; Sitasuwan T; Charatcharoenwitthaya P; Phisalprapa P
Medicine (Baltimore); 2021 Nov; 100(44):e27640. PubMed ID: 34871234
[TBL] [Abstract][Full Text] [Related]
54. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.
Ciardullo S; Sala I; Perseghin G
Diabetes Res Clin Pract; 2020 Sep; 167():108358. PubMed ID: 32745698
[TBL] [Abstract][Full Text] [Related]
55. High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population.
Sepulveda-Villegas M; Roman S; Rivera-Iñiguez I; Ojeda-Granados C; Gonzalez-Aldaco K; Torres-Reyes LA; Jose-Abrego A; Panduro A
PLoS One; 2019; 14(1):e0208926. PubMed ID: 30608932
[TBL] [Abstract][Full Text] [Related]
56. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.
Kuroda H; Fujiwara Y; Abe T; Nagasawa T; Oguri T; Noguchi S; Kamiyama N; Takikawa Y
PLoS One; 2021; 16(4):e0249493. PubMed ID: 33826669
[TBL] [Abstract][Full Text] [Related]
57. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
Fishman J; O'Connell T; Parrinello CM; Woolley JJ; Bercaw E; Charlton MR
J Health Econ Outcomes Res; 2024; 11(1):32-43. PubMed ID: 38370007
[No Abstract] [Full Text] [Related]
59. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
60. Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease.
Blank V; Petroff D; Boehlig A; Heinze A; Karlas T; Berg T; Wiegand J
Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):686-692. PubMed ID: 35102112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
